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Abstract

Informed consent statement: Patients were not required to
give informed consent to the study because the analysis used
anonymous clinical data that were obtained after each patient
agreed to treatment by written consent.

AIM: To elucidate causes for false negative magnetic
resonance imaging (MRI) exams by identifying imag
ing characteristics that predict viable hepatocellular
carcinoma (HCC) in lesions previously treated with loco
regional therapy when obvious findings of recurrence
are absent.

Conflict-of-interest statement: We have no financial relation
ships to disclose.
Data sharing statement: No additional data are available.

METHODS: This retrospective institutional review
board-approved and Health Insurance Portability and
Accountability Act-compliant study included patients
who underwent liver transplantation at our center
between 1/1/2000 and 12/31/2012 after being treated
for HCC with locoregional therapy. All selected patients
had a contrast-enhanced MRI after locoregional
therapy within 90 d of transplant that was prospectively
interpreted as without evidence of residual or recurrent
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the use is non-commercial. See: http://creativecommons.org/
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diagnosed . These criteria were validated in untreated
lesions and therefore do not apply to lesions after treat
ment with locoregional therapy. Although certain imaging
findings are associated with the presence of viable HCC
in a treated lesion there is currently no formal system to
assess the probability of viable tumor.
Magnetic resonance imaging (MRI) is commonly used
status post locoregional therapy to evaluate for recurrent
or residual viable tumor. Because the hallmark of HCC
is avid arterial-phase enhancement, dynamic imaging
following gadolinium-based contrast administration
should be a core component of the examination. Arterialphase enhancement following locoregional therapy has
a reported sensitivity and specificity of 82% to 100%
[2,3]
and 79% to > 90% respectively . Subtle arterial-phase
enhancement can be obscured in treated lesions as
they often demonstrate heterogeneous high signal
on T1-weighted images due to the presence of blood
[4]
products (Figure 1). HCC is a very cellular tumor and
will typically restrict the diffusion of water molecules
giving it high signal on diffusion-weighted imaging (DWI)
and corresponding low signal on the computer gene
rated apparent diffusion coefficient map. Diffusion
restriction following locoregional therapy has a reported
sensitivity and specificity of 61% to 75% and 88% to
[2,3]
> 90% respectively . Identifying restricted diffusion
in treated areas is complicated by the fact that these
areas typically demonstrate high signal on T2-weighted
images due to fibrosis (Figure 2), appearing as T2 shine
through on DWI. Signal intensity on T2-weighted images
is not typically helpful as it is affected by treatment
and can be variable, although it is typically mildly to
moderately hyperintense. Signal intensity on precontrast
T1-weighted images is quite variable and generally not
helpful. HCC is usually hypointense or isointense but can
be hyperintense with intratumoral fat.
Unresectable HCC is often treated with locoregional
therapy to decrease disease burden and as a bridge
to transplant. In these patients accurate assessment
of tumor response is integral to directing patient care.
False negative MRI exams are due to a number of
factors including technical limitations and inherent MR
signal alteration of the treated areas. In addition there
is no formal system for evaluating treated lesions. The
goal of this study was to retrospectively determine
which MRI features were most predictive of histological
findings of residual or recurrent HCC in a population
that does not demonstrate obvious recurrence.

tumor. Retrospectively, 2 radiologists, blinded to clinical
and pathological data, independently reviewed the pretransplant MRIs for 7 imaging features. Liver explant
histopathology provided the reference standard, with
clinically significant tumor defined as viable tumor ≥ 1.0
cm in maximum dimension. Fisher’s exact test was first
performed to identify significant imaging features.
RESULTS: Inclusion criteria selected for 42 patients
with 65 treated lesions. Fourteen of 42 patients (33%)
and 16 of 65 treated lesions (25%) had clinically
significant viable tumor on explant histology. None of
the 7 imaging findings examined could reliably and
reproducibly determine which treated lesion had viable
tumor when the exam had been prospectively read as
without evidence of viable HCC.
CONCLUSION: After locoregional therapy some treated
lesions that do not demonstrate any MRI evidence of
HCC will contain viable tumor. As such even patients
with a negative MRI following treatment should receive
regular short-term imaging surveillance because some
have occult viable tumor. The possibility of occult tumor
should be a consideration when contemplating any
action which might delay liver transplant.
Key words: Hepatocellular carcinoma; Transarterial
chemoembolization; Tumor recurrence; Locoregional
therapy; Imaging surveillance
© The Author(s) 2016. Published by Baishideng Publishing
Group Inc. All rights reserved.

Core tip: Hepatocellular carcinoma (HCC) is often
treated with locoregional therapy such as transarterial
chemoembolization as a bridge to transplantation.
Detecting residual or recurrent tumor within these
treated lesions is challenging and some treated lesions
that do not demonstrate any magnetic resonance
imaging (MRI) evidence of HCC will contain foci of
viable tumor. Regular, short-term imaging surveillance
is clinically important for patients being considered for
liver transplantation even when prior MRIs have been
negative and the possibility of a false negative MRI
exam needs to be considered when managing these
patients.
Becker-Weidman D, Civan JM, Deshmukh SP, Roth CG, Herrine
SK, Parker L, Mitchell DG. Hepatocellular carcinoma after
locoregional therapy: Magnetic resonance imaging findings in
falsely negative exams. World J Hepatol 2016; 8(16): 685-690
Available from: URL: http://www.wjgnet.com/1948-5182/full/
v8/i16/685.htm DOI: http://dx.doi.org/10.4254/wjh.v8.i16.685

MATERIALS AND METHODS
Patient and lesion inclusion criteria

This retrospective study was approved by our insti
tutional review board and was compliant with the
Health Insurance Portability and Accountability Act.
Our study included patients with HCC who underwent
liver transplantation at our center between 1/1/2000
and 12/31/2012 after being treated with locoregional
therapy. Inclusion criteria selected patients that had a

INTRODUCTION
The American College of Radiology developed the
liver imaging reporting and data system (LI-RADS)
to standardize how hepatocellular carcinoma (HCC) is
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Figure 1 Treatment-related signal alterations on T1-weighted images. A 59-year-old man with HCV cirrhosis and a segment Ⅴ LI-RADS 5B lesion measuring up
to 3.6 cm. Fat-saturated T1-weighted precontrast (A) and arterial-phase (B) images demonstrate a 3.6 cm enhancing focus of viable tumor (B, arrow) within an area
previously treated with TACE. Mass could not be visualized upon selective angiography so repeat TACE was not performed. Non-contrast CT from a radiofrequency
ablation procedure (C) demonstrates an electrode positioned within the tumor. One month later a fat-saturated T1-weighted precontrast image (D) demonstrates
peripheral high signal related to hemorrhage from coagulative necrosis (D, arrow). LI-RADS: Liver imaging reporting and data system; TACE: Transarterial
chemoembolization; HCV: Hepatitis C virus.
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Figure 2 Treatment-related signal alterations on T2-weighted images. A 63-year-old man with HCV/EtOH cirrhosis and a segment Ⅶ LI-RADS 5B lesion
measuring 2.4 cm × 1.8 cm. T2-weighted image (A) just superior to the segment Ⅵ lesion before treatment demonstrates a cirrhotic liver with homogeneous low
signal intensity. Non-contrast CT (B) performed immediately after a TACE procedure shows high attenuation Lipiodol® in segment Ⅶ confirming that the appropriate
segment was treated. T2-weighted image (C) from an MRI performed one month later shows high signal intensity in the area that was treated due to fibrotic change.
Precontrast (D) and arterial-phase images (E) from that exam demonstrate that the treated area is completely necrotic. LI-RADS: Liver imaging reporting and data
system; TACE: Transarterial chemoembolization; HCV: Hepatitis C virus; CT: Computed tomography; MRI: Magnetic resonance imaging.

contrast-enhanced MRI after locoregional therapy within
90 d of transplant that was prospectively interpreted as
without evidence of residual or recurrent tumor. Patients
were identified through our electronic medical record.
While HCC is a radiologic diagnosis, subcentimeter
lesions cannot be designated as “definite” HCC by either
the American Association for the Study of Liver Diseases
or the LI-RADS criteria in recognition of the fact that

WJH|www.wjgnet.com

early tumors may not demonstrate hypervascularity and
technical limitations preclude adequate assessment
[1,5]
of lesions below this threshold . Therefore, we con
sidered foci of HCC identified on explant significant for
the purpose of our study only if it measured ≥ 1.0 cm
in maximal diameter.
Foci of viable tumor detected histologically on
explant, distinct from a previously treated lesion were
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not included in our analysis. These foci were treated
as incidental findings as our current analysis regards
the MRI findings in lesions previously identified as HCC
subsequently undergoing treatment.

that 488 patients had a liver transplant at our center
between 1/1/2000 and 12/31/2012, of which 167
(34.2%) had HCC, all of whom were treated with loco
regional therapy prior to transplant. Of these patients,
84 (50.3%) had findings suspicious for recurrent or
residual HCC on the pre-transplant MRI, 24 (14.4%)
underwent locoregional treatment between the pretransplant MRI and transplant, 16 (9.6%) had the pretransplant MRI over 90 d before transplant, and 1 (0.6%)
did not receive intravenous contrast and were excluded
from our study. Patient accrual details are presented in
Figure 3. The final cohort of 42 patients (mean age, 59
years; age range, 46-73 years) included 34 men (mean
age, 59 years; age range, 46-73 years) and 8 women
(mean age, 59 years; age range, 53-70 years). Patients
had cirrhosis secondary to hepatitis C (n = 29), hepatitis
C and alcohol abuse (n = 5), alcohol abuse (n = 4),
nonalcoholic steatohepatitis (n = 1), or an unknown
cause (n = 3). MRI was performed an average of 40 d
before transplant (range, 1-89 d).
Prior to transplant 33 (79%) patients were treated
with transarterial chemoembolization (TACE) only, 3
(7%) were treated with radiofrequency ablation only,
2 (5%) were treated with radioactive embolization
only, 1 (2%) was treated with bland transarterial embo
lization only, and 3 (7%) were treated with TACE and
radiofrequency ablation.

MR image analysis

All MRI data sets were reviewed on a workstation
equipped with image review software (iSite, version
3.6; Philips, Andover, MA). Retrospective image inter
pretations were performed independently by two
body MRI specialists, each with more than 10 years of
experience. The study coordinator, a radiology resident,
prepared the exams for review by correlating the
lesions described in the explant pathology report with
the treated lesions on the MRI, marking the lesions to
be evaluated with an arrow. Exams were reviewed in
random order by the interpreting radiologists, who were
blinded to all other patient history, including pathology
and other imaging results.
Each liver lesion was assessed by the interpreting
radiologist for the presence or absence of: Arterial-phase
nodular enhancement, arterial-phase non-nodular en
hancement, gradual enhancement, partial or complete
T1 signal hypointensity, partial or complete T2 signal
hyperintensity, lipid as determined by comparison of
in-phase and opposed-phase images, and restricted
diffusion if DWI was performed. Findings were recorded
in prepared data sheets.

Reference histopathologic analysis

Gross pathology and histopathologic analysis

The 42 patients who met our inclusion criteria included
18 (43%) who had no viable tumor, 10 (24%) who had
viable tumor that was considered clinically insignificant,
and 14 (33%) who had at least one focus of clinicallysignificant viable tumor on explant pathology. Two
patients had two foci of clinically-significant viable
tumor. The explant Pathology report mentioned a single
lesion in 27 patients (64%), 2 lesions in 9 patients
(21%), 3 lesions in 3 patients (7%), 4 lesions in 2
patients (5%), and 5 lesions in 1 patient (3%) for a
total of 65 treated lesions. Sixteen treated lesions (25%)
had clinically significant viable tumor (mean size, 1.5
cm; range, 1.0-3.5 cm), 13 treated lesions (20%) had
a focus of tumor < 1.0 cm (mean size, 0.5 cm; range,
0.1-0.9 cm), and 36 (55%) treated lesions had no viable
tumor.

All explanted livers were received as surgical resection
specimens. Each explant was serially sectioned in
contiguous slices at 5 mm intervals, and processed
for routine Hematoxylin and Eosin stains. These slides
were prospectively reviewed for the presence of viable
HCC and the pathology report produced was used to
retrospectively correlate the histologic findings with the
pretransplant MRI.

Statistical analysis

Statistical review of the study was performed by a
biomedical statistician. Statistical software (SAS version
9.4; SAS Institute, Cary, NC) was used for all data
analysis. Fisher’s exact test was first performed to iden
tify significant imaging features in a bivariate analysis
followed by a step-wise logistic regression if more than
one variable was significant. The significance threshold
was set at a P-value of 0.05 and any variable with P >
0.05 was removed from the model and determined to be
insignificant. The agreement level between readers was
measured by using k coefficient. We defined k values
for level of agreement as follows: 0.81-0.99, almost
perfect agreement; 0.61-0.80, substantial agreement;
0.41-0.60, moderate agreement; 0.21-0.40, fair agree
[6]
ment; and 0.01-0.20, slight agreement .

MR image and statistical analysis

Of the 42 patients, 15 received gadoextate disodium
(Eovist) (36%), 13 received gadopentate dimeglumine
(Magnevist) (31%), 8 received gadobutrol (Gadavist)
(19%), and 6 received gadobenate dimeglumine (Multi
Hance) (14%). DWI was only performed in 19 patients
(45%) as DWI was not included as a part of our routine
MRI exam of the abdomen until 2011.
For reader #1 “arterial-phase non-nodular enhan
cement” and “partial or complete T1 signal hypoin
tensity” were significant predictors of viable tumor. For
reader #2 “partial or complete T2 signal hyperintensity”
was the sole significant predictor of viable tumor.

RESULTS
Patients

A search of our electronic medical record showed

WJH|www.wjgnet.com

688

June 8, 2016|Volume 8|Issue 16|

Becker-Weidman D et al . MRI findings after locoregional therapy
Table 1 P -values and Kappa values associated with the 7 different imaging features
P -values
Reader #2

0.44
0.25
0.47
0.21
0.047a
0.56
N/A1

0.14
0.008b
0.15
0.001b
0.47
0.44
N/A1

Arterial-phase nodular enhancement
Arterial-phase non-nodular enhancement
Gradual enhancement
Partial or complete T1 signal hypointensity
Partial or complete T2 signal hyperintensity
Lipid
Restricted diffusion
a,b

Kappa values

Reader #1

0.37 (fair agreement)
0.23 (fair agreement)
0.10 (slight agreement)
0.15 (slight agreement)
0.07 (slight agreement)
-0.03 (no agreement)
N/A1

P-values reached significance; 1Could not be assessed due to collinearity. N/A: Not applicable.

488 patients had a liver transplant at our
institution between 1/1/2000 and 12/31/2012

DISCUSSION
Retrospective review of true negative and false negative
MR exams did not identify any subtle findings that can
reliably and reproducibly indicate the presence of viable
HCC in studies that were prospectively interpreted as
negative. T1 and T2 signal intensity are highly variable
after locoregional therapy and are not reliable indicators
of viable tumor. Delayed enhancement is often seen
after treatment and indicates fibrosis. Arterial-phase
enhancement is associated with viable tumor but may
be subtle or absent and has a reported sensitivity of as
[2]
low as 82% . In other words, some patients who do
not have evidence of HCC on MRI will have viable tumor
on explant pathology.
A limitation of this study was the low level of agree
ment between readers. This can be partially explained
due to the low number of “positive” imaging features.
When there is a low base rate a small number of
discordant findings will have a disproportionately large
[7]
effect on Cohen’s kappa coefficient . Agreement re
garding enhancement characteristics is only slight
to fair because any case that demonstrated obvious
enhancement was prospectively read as suspicious
for viable HCC and excluded from our study. The only
cases that remained were those that demonstrated
subtle enhancement. Agreement for signal intensity on
T1- and T2-weighted images is only slight due to the
inherent difficulty in classifying a highly heterogeneous
area. That being said the low kappa value limits the
value and reliability of any imaging finding that was
positively associated with viable HCC. Therefore, we do
not propose that signal intensity on unenhanced T1weighted or T2-weighted images is predictive of viable
tumor. It is possible that non-nodular arterial-phase
enhancement is predictive of viable tumor but this find
ing was not reliable enough in our study for clinical use.
Another limitation was the inconsistency of the
explant pathology reports. Some pathology reports
measured the size of the viable component or state
the percentage of necrosis within the measured
treated lesion, whereas, other reports used subjective
terminology such as “partially necrotic” or “largely
necrotic” which made exact measurement of the viable
component difficult. Another problem was that some of

321 patients did not have HCC

167 patients with liver transplant had HCC
84 patients had evidence of viable
tumor on pretransplant MRI
83 patients with liver transplant and HCC without
evidence of viable tumor on pretransplant MRI
24 patients had locoregional therapy
between MRI and transplant, 16 patients
had MRI over 90 d prior to transplant, and 1
patient did not receive intravenous contrast
42 patients without evidence of viable tumor on a
contrast-enhanced MRI performed less than 90 d prior
to transplant with no treatment between pretransplant
MRI and transplant

Figure 3 Patient accrual flowchart. HCC: Hepatocellular carcinoma; MRI:
Magnetic resonance imaging.

There was fair agreement for arterial-phase nodular
enhancement and non-nodular enhancement (k =
0.37, 0.23 respectively); slight agreement for gradual
enhancement, partial or complete T1 signal hypoin
tensity, and partial or complete T2 signal hyperintensity
(k = 0.07, 0.10, 0.15 respectively); and no agreement
for the presence of lipid (k = -0.03). The P-values and
kappa values are presented in Table 1.

Patient outcomes

There was a single post-transplant recurrence in the 18
patients without viable tumor (mean length of followup,
4.9 years; range, 1.1-9.0 years). There was a single
recurrence in the 10 patients with clinically insignificant
cancer (mean length of followup, 5.2 years; range,
2.6-13.4 years). There was a single recurrence in the
14 patients with clinically significant viable tumor (mean
length of followup, 3.4 years; range, 0.2-7.1 years).
One patient with only 0.2 years of followup died from a
stroke.

WJH|www.wjgnet.com

689

June 8, 2016|Volume 8|Issue 16|

Becker-Weidman D et al . MRI findings after locoregional therapy
in patients with HCC treated with locoregional therapy even when prior MRIs
have been negative due to the possibility of a false negative exam.

the treated lesions demonstrated partial diffuse necrosis
and contained only microscopic islands of tumor. These
lesions are considered viable by histology but impossible
to identify by imaging.
Noting the limitations above it is clear that occa
sionally treated lesions without evidence of viable HCC
by MRI can contain foci of viable tumor. This supports
the utilization of regular short-term imaging surveillance
even when prior MRIs have been negative and is clini
cally important for patients being considered for liver
transplantation. For example, a decision to delay trans
plant to allow treatment of underlying chronic viral
hepatitis C should be made with caution, without overreliance on a sense of security suggested by surveillance
imaging with no definite evidence of viable HCC. The
possibility of a false negative MRI exam needs to be
considered when managing patients after locoregional
therapy.

Terminology

Diffusion-weighted imaging: MRI sequence that measures random Brownian
motion of water molecules within a voxel of tissue; LI-RADS: Set of terminology
developed by the American College of Radiology to standardize the reporting
of imaging findings of liver lesions; Locoregional therapy: Transarterial and/or
local ablative therapy.

Peer-review

This is an interesting manuscript providing information for an easily neglected
field. It is thus of value to be considered for publication.
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